COMPASS Beats 22 Immunotherapy Prediction Methods in Leave-One-Out Evaluation
marinkazitnik · x · 2026-07-03
In leave-one-out cross-validation, COMPASS improved average accuracy by 8.5% and precision-recall AUC by 15.7%, outperforming 22 commonly used biomarkers and predictive models while achieving the highest cross-cohort transfer generalization rate. Even when completely excluding a specific cancer type, drug class, or checkpoint target during training, the model maintained its performance on the excluded categories, indicating its ability to capture anti-tumor immune biological patterns transferable across cancer types.
More from Research
- Causal-only attention for non-generative tasks is wasteful, argues HF engineer — antoine_chaffin · 2026-09-11
- Catholic University of Chile researcher: scaling AI feedback is key to sustainable medical education — julianvarascom · 2026-09-11
- Nature paper images cellular activity across all organs, revealing body-wide circuits — arjunrajlab · 2026-09-11
- SignNet 1M Dataset Released for Sign Language Research — ducha_aiki · 2026-09-11
- ECCV26 Oral: Flow Matching Enables Single-Stage Multi-View Point Cloud Registration — ducha_aiki · 2026-09-11
- InFlux++ Method Released — ducha_aiki · 2026-09-11